Investors in Summit Therapeutics urged to join probe after stock drops on clinical trial update

Johnson Fistel, PLLP is investigating claims for investors in Summit Therapeutics following a sharp stock price drop after the company disclosed challenges in its HARMONi-3 Phase III clinical trial. The investigation focuses on whether Summit's executives complied with federal securities laws after revealing a tougher statistical bar for interim analysis and a recommendation to continue the study. Investors who suffered losses are encouraged to join the investigation to potentially recover their investments. This legal action highlights concerns about transparency and investor protection in biotech trial disclosures.